SEARCH BY NAME

BROWSE

Browse Australian delisted companies

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Browse terminated Australian managed funds

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

REVA MEDICAL, INC (RVA)

Click here for free access to this company's:
ASX, Legal & CGT Status

SHARE PRICES

(updated at weekends)

Former (or subsequent) names

 

Shareholder links

Our website ranking of RVA: rating 4
(4 out of 5)
COMPANY WEBSITE:

 

REGISTRY:
Computershare, Level 3, 60 Carrington Street, Sydney NSW 2000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 2 8235 8150
RegistryWebsite RegistryEmail

Company details

Address: 5751 Copley Drive San Diego, CA 92111
Tel:  (858) 966-3000 Fax: (858) 966-3099

Date first listed: 23/12/2010
Company Secretary: Leigh Elkolli
Sector:  INC
Industry Group: Health Care Equipment & Services
Activities: Development of medical devices, specifically bioresorbable stent products
OFX Transferring Money Internationally to Free

Shareholders in this company should consider crystallising a capital loss in 2020/21 by selling their worthless shares, which they can achieve online by entering transaction details here. While this usually makes good economic sense, we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person.

13/08/2020

delisted from the close of trading on Wednesday, 28 August 2019 pursuant to Listing rule 17.15.

28/08/2019

we understand this company failed to pay its annual listing fee on due date and ASX has accordingly removed it from the official list

28/08/2019

The company has not paid their annual listing fees in respect of the year ending 30 June 2020 but the securities are already suspended from official quotation.

22/08/2019

The company has received an additional $1.2 million in funding as part of the April 2019 senior secured credit facility to continue to support operations on an interim basis. The funding is a multi-draw term loan and has been made available by existing lenders to the company.

05/08/2019

The company has executed a credit and guaranty agreement for a $3.8 million, Senior Secured Credit Facility to fund operations on an interim basis. The funding is a Multi-Draw Term Loan and has been made available by existing lenders to the Company. In connection with the Agreement, the Company will pay approximately $0.8 million in fees, resulting in net funding of $3 million. Additionally, REVA announced that the Company entered into an amendment to that certain Exclusive License Agreement Number 2, dated 1 July 2010, by and between Rutgers, The State University of New Jersey and the Company related to the composition and coating of the Company's bioresorbable scaffolds and its other biomaterial products.

08/04/2019

The company has secured a letter of commitment for up to $3 million of debt financing to fund operations on an interim basis. The funding will be made available by existing lenders to the Company. The funding is subject to the negotiation and execution of definitive agreements and a further announcement will be made once those agreements are executed. The funding is to address the Company's immediate financial needs on an interim basis, but the Company remains in discussions about a broader restructure to address the Company's outstanding indebtedness and capital structure moving forward.

25/03/2019

The company is extending the voluntary suspension of trading until it can finalise its plans and provide the market with an accurate update on its future plans. The company expects to be able to make an announcement regarding its finalised plans by 21 March 2019.

13/03/2019

S&P DJI Announces March 2019 Quarterly Rebalance.

08/03/2019

The voluntary suspension is expected to continue until plans are finalised and an announcement is made to the ASX. The company is expecting that it will be able to make an announcement by 13 March 2019.

06/03/2019

The company requests the voluntary suspension of its securities continue until it can finalise its plans and provide the market with an accurate update on its future plans. The suspension is expected to continue until the financial debt and or equity raising details are finalised and an announcement is made to the ASX in this regard. It is expected to be able to do so by 6 March 2019.

25/02/2019

The company issues a response to ASX Appendix 4C Query Letter.

22/02/2019

The securities of Reva Medical, Inc. will be suspended from quotation immediately under Listing Rule 17.2, at the request of RVA, pending the release of an announcement regarding capital raising activities.

20/02/2019

listed entity carried for record purposes only

23/12/2010

 

Click here for free access to this company's:
ASX, Legal & CGT Status

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.
Loading comments....  Most recent comments

I would like to know what is the situation with this company. I have shares and have had no correspondence in relation to where they are and if they are worth anything. Very poor communication.

12/01/2020 11:53:49

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box. If an image appears, enter the word/figures you see in the image.

    loading Posting your comments. Please wait...

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNATURENUMBERPRICEAMOUNT
    29/06/2018Regina Groves98,157$0.207$20,309
    29/06/2018Robert Thomas163,596$0.207$33,848
    29/06/2018Stephen Oesterle163,596$0.207$33,848
    29/06/2018Robert Stockman327,191$0.207$67,696
    29/06/2018Ray Larkin196,315$0.207$40,618

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Ray LarkinChairman14/07/2017
    Leigh ElkolliCFO04/01/2019
    Ross BreckenridgeNon Exec Director29/01/2015
    Robert StockmanNon Exec Director01/12/1999
    Brian DoveyDirector12/06/2001
    Stephen OesterleDirector05/02/2018
    Robert ThomasDirector28/07/2010

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Regina GrovesDirector, CEO21/09/201525/03/2019
    Brandi RobertsCFO28/08/201704/01/2019
    Scott HuennekensNon Exec Director26/03/201516/05/2018
    Katrina ThompsonCFO28/08/2017
    Gordon NyeDirector16/05/200114/07/2017
    Anne KeatingDirector01/10/201001/06/2017
    James SchiroDirector09/11/201025/07/2014

    Date of first appointment, title may have changed.